Marja-Liisa Sumelahti MD, PhD, Specialist in Neurology, Faculty of Medicine and Health Technology, Tampere University, Finland.  Sweden, Denmark, Norway and Finland have independently developed their regulations for reimbursing treatment with anti-CGRP monoclonal antibodies, resulting in different levels of access to treatment and inconsistent eligibility criteria.

Marja-Liisa Sumelahti MD, PhD, Specialist in Neurology, Faculty of Medicine and Health Technology, Tampere University, Finland. Sweden, Denmark, Norway and Finland have independently developed their regulations for reimbursing treatment with anti-CGRP monoclonal antibodies, resulting in different levels of access to treatment and inconsistent eligibility criteria.

Marja-Liisa Sumelahti MD, PhD, Specialist in Neurology, Faculty of Medicine and Health Technology, Tampere University, Finland.&nbsp; Sweden, Denmark, Norway and Finland have independently developed their regulations for reimbursing treatment with anti-CGRP monoclonal antibodies, resulting in different levels of access to treatment and inconsistent eligibility criteria.

Share Nordic Reimbursement Guidelines for aCGRP Treatment – Finland

Sign up to save your podcasts

Nordic Reimbursement Guidelines for aCGRP Treatment – Finland

Nordic Reimbursement Guidelines for aCGRP Treatment – Finland